Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORC-13661 for the Prevention of Amikacin-Induced Hearing Loss in NTM Disease
NCT05730283Phase 2Recruiting
- Sponsor
- Kevin Winthrop
- Start
- Jun 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of ORC-13661 in drug-induced ototoxicity, sponsored by Kevin Winthrop. Started Jun 2025; status: recruiting.
02
Drugs
ORC-13661
03
Conditions
drug-induced ototoxicity
Beyond the preview
Go deeper on NCT05730283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05730283.